References
- Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104. doi:10.1056/NEJMoa131090724251359
- Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–962. doi:10.1016/S0140-6736(13)62343-024315724
- Caldeira D, Barra M, Pinto FJ, et al. Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and metaanalysis. J Neurol. 2015;262:516–522. doi:10.1007/s00415-014-7462-025119841
- Pollack Jr CV, Reilly PA, Van Ryn J, et al. Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med. 2017;377(5):431–441.
- Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380:1326–1335. doi:10.1056/NEJMoa181405130730782
- Steffel J, Verhamme P, Potpara TS, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1–64.29300945
- Lip GYH, Banerjee A, Boriani G et al. Antithrombotic Therapy for Atrial Fibrillation, CHEST Guideline and Expert Panel Report. CHEST 2018; 154(5):1121-120130144419
- Raval AN, Cigarroa JE, Chung MK, et al. Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement from the American Heart Association, Circulation. 2017;135(10):e604–e633
- Brinkman HJM. Prothrombin Complex Concentrate, a General Antidote for Oral Anticoagulation. In: Anticoagulation Therapy. London, UK: IntechOpen; 2016, 79–109.
- Zahir H, Brown KS, Vandell AG, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation. 2015;131:82–90. doi:10.1161/CIRCULATIONAHA.114.01344525403645
- Daiichi Sankyo Europe GmbH. Lixiana (Edoxaban) summary of product characteristics. Daiichi Sankyo Europe GmbH; 5 2019.
- Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371:2141–214225371966
- Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc. 2016;5:5.